Alto Neuroscience, Inc.
ANRO
$2.28
$0.010.44%
NYSE
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 21.61M | 17.54M | 13.46M | 10.36M | 7.52M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 68.61M | 63.38M | 54.21M | 44.99M | 37.81M |
| Operating Income | -68.61M | -63.38M | -54.21M | -44.99M | -37.81M |
| Income Before Tax | -61.43M | -57.45M | -49.81M | -42.44M | -36.31M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -61.43 | -57.45 | -49.81 | -42.44 | -36.31 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -61.43M | -57.45M | -49.81M | -42.44M | -36.31M |
| EBIT | -68.61M | -63.38M | -54.21M | -44.99M | -37.81M |
| EBITDA | -68.11M | -62.93M | -53.83M | -44.61M | -37.44M |
| EPS Basic | -2.55 | -4.95 | -6.77 | -8.51 | -9.72 |
| Normalized Basic EPS | -1.59 | -3.10 | -4.23 | -5.32 | -6.08 |
| EPS Diluted | -2.55 | -4.95 | -6.77 | -8.51 | -9.72 |
| Normalized Diluted EPS | -1.59 | -3.10 | -4.23 | -5.32 | -6.08 |
| Average Basic Shares Outstanding | 98.25M | 75.25M | 52.03M | 28.83M | 14.92M |
| Average Diluted Shares Outstanding | 98.25M | 75.25M | 52.03M | 28.83M | 14.92M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |